MOTS-c (mitochondrial-derived peptide)
MOTS-c: What The Studies Actually Say
Your body makes MOTS-c on its own. No study that gave it to people has published results. The running old mice and the lean fat-fed mice are real, but they are mice. Here is what the research actually found.
Updated 22 September 2026
Before you read this
This page explains what published studies found. That is all it is. It is not medical advice, and it is not instructions for using anything. Nothing here is meant to find, treat, cure or stop any illness. The compounds discussed on this site, retatrutide included, are not approved by the FDA for use in people. Research compounds are sold for laboratory use only — not for use in humans or animals. A study tells you what happened to the people in it. It does not tell you what would happen to you. What you do with what you read here is your responsibility, so talk to a doctor first. This page is published by Ascend Vials, which sells research compounds.
Read the full guide
Confirm you have read the notice above and enter an email address. We will send you a link back to this guide, and sometimes an email when we publish a new one. You can unsubscribe any time.
Most of what you have heard about MOTS-c comes from mice. No study that gave it to people has ever published results.
Here is what the actual research found. Every claim has a link. Read them yourself.
The 30-second version
- MOTS-c is a tiny peptide your body already makes. Its code sits in the DNA of your mitochondria, the power plants inside your cells.
- No study of MOTS-c given to people has reported. The FDA found no clinical studies and no human exposure data. The first real trial began in China in 2026.
- The exciting results — old mice running twice as long, fat-fed mice staying lean — were all in mice.
- The only published human injection trial used a different, modified molecule. Liver fat fell just as much on the fake shot.
- The "longer life" claim is a mouse trend that was not statistically significant.
- It is not approved anywhere. An FDA advisory panel voted 7–5 to let pharmacies mix it, but that vote is not binding and no rule has followed. It is banned in sport at all times.
- Nothing sold online has been shown to match what the studies used. No study has checked.
What it is
MOTS-c is a chain of 16 amino acids that your body makes naturally. A team at the University of Southern California (USC) described it in 2015. Cell Metabolism, 2015
Here is the unusual part. Almost all of your DNA sits in the nucleus of each cell. But your mitochondria carry a little DNA of their own, and the code for MOTS-c is hidden inside one of their genes. The team proposed that it works like a hormone, carrying signals around the body. It has been found in human blood and muscle. Cell Metabolism, 2015 · Nature Communications, 2021
No published study has given MOTS-c to a person
In May 2026 the FDA reviewed everything it could find. It found no clinical studies and no human exposure data for MOTS-c, by any route. FDA briefing, 2026
The first real trial is running now, in China. It aims to enroll 120 adults with prediabetes and extra weight, who get MOTS-c or a fake shot for 12 weeks. It started in February 2026. Its main data are due around February 2027. In September 2026 we found no other registered trial giving MOTS-c itself to people. Trial record · Registry search
The closest thing: a cousin called CB4211
A company called CohBar made a modified version of MOTS-c, called CB4211. It is a different molecule. It is the only MOTS-c-based drug with published results from people getting shots.
The main part of its trial took 23 obese adults with fatty liver. They stayed in a clinic, ate a set diet, and got a daily shot of CB4211 or a fake shot for 4 weeks. Results were reported for 20. AASLD poster, 2021 · Trial record
| Fake shot | CB4211 | |
|---|---|---|
| People | 9 | 11 |
| ALT, a liver-damage marker | +4% | −21% |
| AST, another liver marker | −11% | −28% |
| Fasting blood sugar | 0% | −6% |
| Body weight | — | Only a trend described |
Those three gaps were statistically significant. Now look at liver fat, the thing these patients were picked for:
Liver fat fell in both groups by almost the same amount. The researchers put that down to the healthier clinic diet. So the trial showed no liver-fat effect beyond the fake shot.
Read the fine print too. It is a conference poster, not a peer-reviewed paper. CohBar paid for it, and the last author worked there and owned its stock. And the drug group started with more liver fat (21.1% against 15.9%). AASLD poster, 2021
What your own MOTS-c does
Every other human study measured the MOTS-c people already had. Nobody was given any. That can show what MOTS-c goes along with. It cannot show what a shot of it would do.
Exercise. In 10 inactive young men, one bike ride raised MOTS-c in muscle 11.9 times over. In the blood it rose about 1.6 times, then was back to normal within 4 hours. No group skipped the ride. Nature Communications, 2021 A Swedish-led study of 30 people found only a trend in the blood after endurance exercise, and no rise after weight training. J Appl Physiol, 2021 So the blood result is mixed.
Age. In healthy men, blood MOTS-c was 21% lower at ages 70 to 81 than at 18 to 30. But inside the muscle, older men had about 1.5 times more. Aging, 2020
Weight. Three studies compared people with and without obesity:
| Who | People | MOTS-c in the blood with obesity |
|---|---|---|
| Children and teens, China | 97 | Lower in boys, not in girls |
| Adults, Chile | 20 | No difference |
| Adults, Mayo Clinic, US | 54 | Higher — and unchanged after weight-loss surgery |
Read the whole table. Three studies, three different answers.
Sources: Pediatric Diabetes, 2018 · J Investig Med, 2018 · J Clin Transl Endocrinol, 2026
The test itself. Across studies, reported blood levels differ more than 2,000-fold. Mayo Clinic · China When anti-doping scientists built a more exact test, it could not confirm the levels a common test kit gave for 20 healthy people. Rapid Commun Mass Spectrom, 2019
A gene variant. Some East Asians carry a version of MOTS-c with one building block swapped. Across 27,527 people, men with it had more type 2 diabetes. Women did not. In one group, the extra risk showed up only in the least active men. Aging, 2021
These are patterns, not proof. None of them can show that MOTS-c caused anything.
The exciting part was only shown in mice
Fat-fed mice. Mice on a high-fat diet got MOTS-c every day for 8 weeks, 10 per group. They gained less weight, had lower insulin and built up less liver fat than untreated mice, while eating exactly the same calories. In a separate test, treated mice handled insulin better. On a normal diet, 8 weeks of MOTS-c did not change body weight at all. Cell Metabolism, 2015
Old mice. Mice aged 22 months, old for a mouse, got MOTS-c daily for 2 weeks. On a treadmill they ran twice as long and 2.16 times as far as untreated old mice. 17% reached top speed. None of the untreated ones did. Nature Communications, 2021
Longer life? Not shown. Mice treated from very late in life lived a median 6.4% longer. But the overall survival difference was not statistically significant, so it could be chance. The authors call it a trend and say bigger studies are needed. Nature Communications, 2021
Only the males. In fat-fed mice, males given MOTS-c gained less weight and handled sugar better. Females did not respond at all. Aging, 2021
Other results. In mice, it limited weight gain in a model of menopause, reduced bone loss in the skull, and fully neutralized MRSA, a drug-resistant germ, in a belly infection. J Mol Med, 2019 · Pharmacol Res, 2019 · eLife, 2026
None of this has been tested in people.
How it is supposed to work
These ideas come from cells and mice. None has been confirmed in a person.
In cells, MOTS-c switched on AMPK, the cell's fuel gauge. But blocking AMPK cut its effect by only 16% to 40%, so AMPK is only part of the story. Cell Metabolism, 2015 Under stress, it moved into the cell's nucleus and turned genes on and off. Cell Metabolism, 2018 In obese mice, it lowered myostatin, a protein that holds muscle back. Am J Physiol Endocrinol Metab, 2021
FDA's reviewers say nobody knows what MOTS-c actually latches onto in the body. So nobody can predict which organs it would affect.
It may not even last. In human blood in a test tube, MOTS-c was quickly chopped into pieces. FDA found no study of how long it lasts in an animal or a person. Nobody knows if a shot could reach active levels at all. FDA briefing, 2026
Side effects: nobody has counted
With no published human study, there is no human side-effect record. FDA calls the risks unknown. It found no standard animal safety studies either, including nothing on DNA damage, pregnancy or cancer. FDA briefing, 2026
What FDA does flag:
- Immune reactions and impurities. FDA says MOTS-c may pose a significant risk of immune reactions, and its impurities can be hard to pin down. FDA safety page An immune reaction could make antibodies that might even block the MOTS-c your body makes. FDA briefing, 2026
- An empty file. FDA's side-effect database had no MOTS-c reports through March 2025. But compounding pharmacies generally do not report side effects. Empty does not mean safe. FDA briefing, 2026
The cousin, CB4211, had no serious side effects in 4 weeks. Mild to moderate reactions at the injection site were the only drug-related problem in more than 1 in 10 people. AASLD poster, 2021 CohBar had suspended the trial in November 2018 to deal with those reactions. It later said the trial's formula was not suitable to develop further, and its attempts at a better one had not worked. CohBar SEC filing, 2023
A warning sign from the lab. In stem cells from the fat of people with obesity, MOTS-c raised ageing markers and an inflammation signal. The treated cells then failed to repair damaged mouse kidneys. Inflamm Regen, 2026
Who did the research
The discovery and the key mechanism, exercise and aging studies came mostly from USC labs. Senior authors there disclosed consulting for CohBar, owning its shares, or both. CohBar is the company that made CB4211. Cell Metabolism, 2015 · Nature Communications, 2021 Even the Swedish exercise study had two USC co-authors. J Appl Physiol, 2021
None of that makes the results wrong. It means you should ask whether other labs can repeat the headline mouse results. That is still an open question.
Is it approved?
MOTS-c is not approved as a drug anywhere we could verify.
- United States: not FDA-approved. FDA briefing, 2026 In 2023 FDA listed it among substances that "raise significant safety risks" when pharmacies mix them. FDA list, 2023 After the nomination was withdrawn, FDA's page moved it to a "previously in category 2" table. The page still carries FDA's safety warning. FDA safety page
- The panel vote. FDA staff then reviewed it on their own. They concluded the case weighs against letting pharmacies use it: poorly characterized, no human safety data, no clinical evidence. FDA briefing, 2026 On July 23, 2026, FDA's advisory panel looked at it for obesity and osteoporosis. It voted 7 to 5, with 2 abstaining, in favor of allowing it. That vote is advice. FDA does not have to follow it, any change needs a formal rule, and it would not make MOTS-c an approved drug. FDA meeting page · PharmExec, 2026 As of 22 September 2026 we found no final rule.
- European Union: no authorized product with MOTS-c, according to FDA's search. FDA briefing, 2026
- China: the trial above is a trial, not an approval. Trial record
- Sport: banned at all times, in and out of competition. WADA 2026 list
- Everywhere else, including Australia: we could not verify its status, so we make no claim.
What is still unknown
- Whether a shot of MOTS-c reaches active levels in a person at all.
- What it binds to, and so which organs it affects.
- Any safe or effective amount for a person.
- Long-term safety: cancer, pregnancy, and immune reactions.
- Whether it changes weight, blood sugar, bones or lifespan in people.
- What a normal blood level even is.
- Whether it works differently in women, or in different ancestries.
What is in the bottle is not what was studied
One more thing.
Every result on this page came from a research lab or a company trial. Not one came from a product bought online.
No study has ever shown that a product sold online as "MOTS-c" is the same thing. Not the same purity. Not the same strength. Not even proof it is the same molecule. "MOTS-c" is not an official drug name, and FDA has seen different salts and altered versions sold under it. FDA calls that a patient safety risk. FDA briefing, 2026
So take every number on this page for what it is. It describes what happened in those studies. It describes nothing else.
How to check a number yourself
You are going to see more claims about MOTS-c. In a reel. In a comment. On somebody's store page.
Here is how to tell a real one from a marketing one. Five questions. About ten seconds each.
1. Is there a link to a study?
A real number comes from a paper you can open. No link means it is a claim, not a result. Search "MOTS-c" on pubmed.gov yourself.
2. Was it people, mice or a dish?
The running, the lean mice and the longer life all come from mice. A mouse doing better is a reason to test people. It is not a result in people.
3. Was MOTS-c given, or just measured?
Almost every human study here only measured the MOTS-c people already had. That shows what it goes along with, not what a shot would do.
4. Was it MOTS-c, or a cousin?
The only human injection trial used CB4211, a different molecule. A result for a cousin is not a result for MOTS-c.
5. Who did the research?
Much of it comes from one university, with authors tied to the company that made the cousin.
Now run those five on this page
Every number above links to its paper. You were told which results come from mice and dishes, which human studies only measured people's own MOTS-c, and that the one injection trial used a different molecule. The lifespan claim has its real label next to it: a trend, not a result.
That is the whole difference: a number you can check, and a number you are asked to believe.
This page has a date on it, near the top. When the trial in China reports, this page changes.
Read the studies yourself
- Discovery paper, Cell Metabolism 2015 — the fat-fed mice and the fuel-gauge idea
- Exercise and old mice, Nature Communications 2021 — the treadmill and lifespan numbers
- CB4211 trial poster, AASLD 2021 — the cousin's human results · its trial record
- CohBar SEC filing, 2023 — the pause and the formula problem
- The trial in China — no results yet · registry search
- FDA briefing document, May 2026 — the fullest safety review
- FDA safety-risk page · FDA list, 2023
- FDA advisory panel, July 2026 · the vote, PharmExec
- WADA 2026 Prohibited List
- Exercise in 30 people, J Appl Physiol 2021
- Age in men, Aging 2020
- The East Asian gene variant, Aging 2021 — also the male-only mouse results
- Obesity studies: China 2018 · Chile 2018 · Mayo Clinic 2026
- Anti-doping test, Rapid Commun Mass Spectrom 2019
- MOTS-c in the nucleus, Cell Metabolism 2018
- Muscle and myostatin, Am J Physiol Endocrinol Metab 2021
- Other mouse results: menopause model, J Mol Med 2019 · bone loss, Pharmacol Res 2019 · MRSA, eLife 2026
- Stem cells from obese donors, Inflamm Regen 2026 — the warning sign
Anything above about amounts describes what a study gave to animals, cells or enrolled people. This is not advice, a plan, or instructions. MOTS-c is not an approved medicine. Research compounds are not for human or animal use.